John-Bjarne Hansen

John-Bjarne Hansen

Auto-generated profile, based on publicly available information

John-Bjarne Hansen

Thrombosis Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
BTBirgitte G. Tøndel
Birgitte G. Tøndel
VMVânia Morelli
Vânia Morelli
JHJohn‐Bjarne Hansen
John‐Bjarne Hansen
SBSigrid K. Brækkan
Sigrid K. Brækkan
Identification of individuals with ischemic stroke at particularly high risk of venous thromboembolism (VTE) is crucial for targeted thromboprophylaxis. To guide clinical decision‐making and development of risk prediction models, increased knowledge on risk factors and biomarkers is needed. Therefore, we set out to identify risk factors and predictors for VTE in people with ischemic stroke by conducting a systematic review of the literature. Medline and Embase were searched from January 1990 and onwards. Studies investigating demographic, clinical, and/or laboratory factors for stroke‐related VTE were considered. Two reviewers screened all retrieved records, independently and in duplicate. Risk of bias assessments were guided by a structured framework (PROSPERO‐ID: CRD42020176361). Of 4674 identified records, 26 studies were included. Twenty‐six demographic, clinical, and laboratory factors associated with increased risk of stroke‐related VTE after multivariable adjustments were identified. The following factors were reported by ≥2 studies: prior VTE, cancer, prestroke disability, leg weakness, increasing lesion volume of the brain infarct, infection, low Barthel Index, increasing length of hospital stay, biochemical indices of dehydration, as well as elevated levels of D‐dimer, C‐reactive protein, and homocysteine. The majority of the studies were of poor quality with moderate or high risk of bias. In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed because there were few high‐quality studies on each factor.

23 June 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PEPaul L. Den Exter
Paul L. Den Exter
SWScott C. Woller
Scott C. Woller
HRHelia Robert-Ebadi
Helia Robert-Ebadi
CMCamila Masias
Camila Masias
PMPierre‐Emmanuel Morange
Pierre‐Emmanuel Morange
FKFrederikus A. Klok
Frederikus A. Klok
Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent recurrent VTE and death, which exposes them to an inherent increased risk of bleeding. Identification of patients at high risk of bleeding, and mitigating this risk, is an essential component of the immediate and long‐term therapeutic management of VTE. The bleeding risk can be estimated by either implicit judgment, weighing individual predictors (clinical variables or biomarkers), or by risk prediction tools developed for this purpose. Management of bleeding risk in clinical practice is, however, far from standardized. International guidelines are contradictory and lack clear and consistent guidance on the optimal management of bleeding risk. This report of the ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease summarizes the evidence on the prediction of bleeding in VTE patients. We systematically searched the literature and identified 34 original studies evaluating either predictors or risk prediction models for prediction of bleeding risk on anticoagulation in VTE patients. Based on this evidence, we provide recommendations for the standardized management of bleeding risk in VTE patients.

28 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
MCMonique J. T. Crobach
Monique J. T. Crobach
RARayna J. S. Anijs
Rayna J. S. Anijs
SBSigrid K. Brækkan
Sigrid K. Brækkan
MSMarianne Tang Severinsen
Marianne Tang Severinsen
JHJens Hammerstrøm
Jens Hammerstrøm
SCSuzanne C. Cannegieter
Suzanne C. Cannegieter
Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and this combination is reported to result in poorer survival compared with cancer alone. This study aimed to investigate the impact of VTE on the survival of patients with cancer in a general population. The Scandinavian Thrombosis and Cancer (STAC) cohort, a population-based cohort including 144 952 participants without previous VTE or cancer, was used. During follow-up, cancer and VTE incidences were registered. “Cancer-related VTE” was defined as VTE diagnosed in patients with overt or occult cancer. The survival of participants without cancer and/or VTE (“disease-free”) was compared with the survival of participants with cancer and cancer-related VTE. Cox regression models with cancer and VTE as time-varying exposures were performed to calculate hazard ratios for death. Subanalyses were performed across cancer types and stages and VTE type (deep vein thrombosis or pulmonary embolism). During follow-up (mean, 11.7 years), 14 621 participants developed cancer, and 2444 developed VTE, of which 1241 were cancer-related. The mortality rates (per 100 person years) for disease-free participants, VTE only, cancer only, and cancer-related VTE were 0.63, 5.0, 9.2, and 45.3, respectively. Compared with patients with cancer only, the risk of death for patients with cancer-related VTE was increased 3.4-fold. Within all cancer types, the occurrence of VTE increased the mortality risk 2.8- to 14.7-fold. In a general population, patients with cancer with VTE had a 3.4-fold higher mortality risk than patients with cancer without VTE, independent of cancer type.

Verified
Journal Article
Open access
PDF file
VMVânia Morelli
Vânia Morelli
SBSigrid Kufaas Braekkan
Sigrid Kufaas Braekkan
JHJohn-Bjarne Hansen
John-Bjarne Hansen
MicroRNAs (miRNAs) are non-coding RNAs that execute their function by targeted downregulation of gene expressions. There is growing evidence from epidemiological studies and animal models suggesting that the expression level of miRNAs is dysregulated in venous thromboembolism (VTE). In this review, we summarize the current knowledge on the role of miRNAs as biomarkers for VTE and provide general insight into research exploring the modulation of miRNA activity in animal models of venous thrombosis. Up to now, published studies have yielded inconsistent results on the role of miRNAs as biomarkers for VTE with most of the reports focused on diagnostic research. The limited statistical power of the individual studies, due to the small sample sizes, may substantially contribute to the poor reproducibility among studies. In animal models, over-expression or inhibition of some miRNAs appear to influence venous thrombus formation and resolution. However, there is an important gap in knowledge on the potential role of miRNAs as therapeutic targets in VTE. Future research involving large cohorts should be designed to clarify the clinical usefulness of miRNAs as biomarkers for VTE, and animal model studies should be pursued to unravel the role of miRNAs in the pathogenesis of VTE and their potential as therapeutic targets.

9 September 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HJHelle Jørgensen
Helle Jørgensen
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
KLKristina Laugesen
Kristina Laugesen
SBSigrid Brækkan
Sigrid Brækkan
JHJohn‐Bjarne Hansen
John‐Bjarne Hansen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Background Although venous thromboembolism (VTE) is a leading cause of morbidity and mortality, and socioeconomic status (SES) affects human health and health behavior, few studies have examined the association between SES and VTE. Objectives We aimed to investigate the association between SES, assessed individually and in a composite score by levels of education, income, and employment status, and incident VTE. Methods We used Danish national registries to identify 51,350 persons aged 25-65 years with incident VTE during 1995-2016. For each case we used incidence density sampling to select five age-, sex-,and index-year-matched controls from the general Danish population (n=256,750). SES indicators, including education, income, and employment status, were assessed one and five years prior to the VTE. We used conditional logistic regression to compute odds ratios (ORs) with 95% confidence intervals (CIs) for VTE according to individual SES indicators and a composite SES score in analyses adjusted for age, sex, and comorbidities. Results Compared to low levels, high educational level (OR 0.74; 95% CI 0.71-0.77), high income (OR 0.70; 95% CI 0.68-0.72), and high employment status (OR 0.66; 95% CI 0.64-0.68) were associated with decreased risk of VTE, even after adjusting for comorbidities. A composite SES score was superior to the individual indicators in assessing VTE risk (OR for high vs. low score: 0.61; 95% CI 0.59-0.63). In sensitivity analysis with SES indicators measured 5 years prior to the VTE, the risk estimates remaine2d essentially the same. Conclusion High levels of both individual SES indicators and a composite SES score were associated with decreased VTE risk.

1 June 1999 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CSCarina Seidel
Carina Seidel
HHHenrik Hjorth-Hansen
Henrik Hjorth-Hansen
BBBjørn Bendz
Bjørn Bendz
Magne BørsetMagne Børset
Magne Børset
Per Morten SandsetPer Morten Sandset
Per Morten Sandset
AWAnders Waage
Anders Waage
Soluble heparin displaces the cytokine hepatocyte growth factor (HGF) from heparan sulphate proteoglycans on the cell surface and in the extracellular matrix into the circulation. We examined serum HGF elevation after heparin injections, and whether there is a difference between unfractionated heparin (UH) and low molecular weight heparin (LMWH) in their ability to increase serum HGF. 20 healthy individuals were randomized to a single injection of intravenous or subcutaneous UH or LMWH. There was a significant increase in HGF from pretreatment values. This HGF was bioactive. When these preparations were compared on the basis of their serum concentrations (anti‐factor Xa activity or molar concentrations), the increase in HGF was greater in individuals receiving UH than LMWH. When UH or LMWH were administered over a 5 d period, the increase in HGF, as well as the difference between treatments to induce HGF, remained stable throughout the treatment. In five patients treated with continuous intravenous heparin infusion HGF was increased throughout the treatment period of 5–7 d. In summary, the rise in bioactive HGF after heparin treatment was stable during continued treatment. UH was more potent in inducing HGF increase than LMWH, both after a single injection and after several days of treatment.